Kolkata, West Bengal -- (SBWIRE) -- 09/24/2013 -- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the Golden Star Resources Ltd. (USA) (NYSEAMEX:GSS), Zalicus Inc(NASDAQ:ZLCS), Dynavax Technologies Corporation (NASDAQ:DVAX).
Golden Star Resources Ltd. (USA) (NYSEAMEX:GSS) shares decreased 7.73% to $0.450. The company on Sept. 17 announce that Angela Parr has joined the Company as its Director, Investor Relations and Corporate Affairs.
Angela is an investor relations professional with over ten years of experience in the natural resources sector, including diamond, gemstone, iron ore and gold mining. She has worked across sub-Saharan Africa, most recently in the West African gold mining sector. Angela started her career in investment banking in South Africa.
Should Investors Buy GSS After Yesterday’s Jump? Find Out Here
Zalicus Inc(NASDAQ:ZLCS) shares decreased 0.67% to $0.775. The company on Sept. 9 announced that it has initiated a Phase 1b clinical study with Z944, its novel oral T-type calcium channel blocker, in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials (LEP). Results from the LEP study are expected in the fourth quarter 2013. The LEP clinical model is a type of experimental medicine study designed to provide both objective and subjective data on a drug's ability to modulate pain signaling.
Additionally, the company on Sept. 3 announced that it has completed patient enrollment in two Phase 2 clinical studies of Z160 for chronic neuropathic pain indications including lumbosacral radiculopathy and postherpetic neuralgia. Top-line results of both studies are expected in the fourth quarter of 2013. Z160 is a first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker in development for chronic neuropathic pain.
How Should Investors Trade ZLCS After The Recent Volatility? Get Free Trend Analysis Here
Dynavax Technologies Corporation (NASDAQ:DVAX) shares decreased 5.48% to $1.19. Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm, on August 16 has commenced an investigation into Dynavax Technologies Corporation to determine whether certain officers and directors of the Company breached their fiduciary duties to shareholders. Dynavax is a clinical-stage biopharmaceutical company focused on the discovery and development of products for the prevention and treatment of infectious and inflammatory diseases. The investigation concerns the clinical trial of Dynavax's lead product candidate, HEPLISAV(TM) ("HEPLISAV"), a Phase III investigational hepatitis B vaccine.
Should Investors Buy DVAX After Yesterday’s Jump? Find Out Here
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)